The structure and mode of action of different botulinum toxins
- 13 November 2006
- journal article
- review article
- Published by Wiley in European Journal of Neurology
- Vol. 13 (s4) , 1-9
- https://doi.org/10.1111/j.1468-1331.2006.01648.x
Abstract
The seven serotypes (A-G) of botulinum neurotoxin (BoNT) are proteins produced by Clostridium botulinum and have multifunctional abilities: (i) they target cholinergic nerve endings via binding to ecto-acceptors (ii) they undergo endocytosis/translocation and (iii) their light chains act intraneuronally to block acetylcholine release. The fundamental process of quantal transmitter release occurs by Ca2+-regulated exocytosis involving sensitive factor attachment protein-25 (SNAP-25), syntaxin and synaptobrevin. Proteolytic cleavage by BoNT-A of nine amino acids from the C-terminal of SNAP-25 disables its function, causing prolonged muscle weakness. This unique combination of activities underlies the effectiveness of BoNT-A haemagglutinin complex in treating human conditions resulting from hyperactivity at peripheral cholinergic nerve endings. In vivo imaging and immunomicroscopy of murine muscles injected with type A toxin revealed that the extended duration of action results from the longevity of its protease, persistence of the cleaved SNAP-25 and a protracted time course for the remodelling of treated nerve-muscle synapses. In addition, an application in pain management has been indicated by the ability of BoNT to inhibit neuropeptide release from nociceptors, thereby blocking central and peripheral pain sensitization processes. The widespread cellular distribution of SNAP-25 and the diversity of the toxin's neuronal acceptors are being exploited for other therapeutic applications.Keywords
This publication has 39 references indexed in Scilit:
- The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitizationPain, 2006
- SV2 Is the Protein Receptor for Botulinum Neurotoxin AScience, 2006
- Angiotensin converting enzyme has an inhibitory role in CGRP metabolism in human skinPeptides, 2006
- The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nervesFEBS Letters, 2006
- A Lack of Antinociceptive or Antiinflammatory Effect of Botulinum Toxin A in an Inflammatory Human Pain ModelAnesthesia & Analgesia, 2006
- Botulinum toxin type A in experimental neuropathic painJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2005
- Is the light chain subcellular localization an important factor in botulinum toxin duration of action?Movement Disorders, 2004
- Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevinNature, 1992
- Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomesFEBS Letters, 1990
- Efficient Analysis of Experimental ObservationsAnnual Review of Pharmacology and Toxicology, 1980